姓名：陈光 职称：教授 职务：基础医学部（医学检验系）主任
主要学习与工作经历：
2004年09月-2010年07月：沈阳药科大学，药学院，药理学博士
2016年04月-2018年03月：The University of Texas Health Science Center at San Antonio，Medical School，博士后
2011年10月-2012年09月：Texas A&M Health Science Center，Institute of Biosciences & Technology，博士后
2010年07月-迄今：台州学院，医学院，教授
主要学术成果与荣誉：
主持国家级和省部级科研和教学项目7项，发表SCI收录论文27篇。兼任中国病理生理学会第三届机能实验教学工作委员会委员，浙江省生理科学会常务理事，浙江省医学会医学科研管理学分会委员，台州市抗癌协会常务理事，第一届台州市医学会肿瘤学分会青年委员会副主委，第九届台州市医学会肿瘤学分会常务理事。
主要研究方向：
1、新药药理与毒理学研究
2、抗肿瘤药物新靶点发现及药理学研究
主要研究/教学论文（第一作者或通讯作者）：
1. Chen G*, Ding XF, Pressley K, Bouamar H, Wang B, Zheng G, Broome LE, Nazarullah A, Brenner AJ, Kaklamani V, Jatoi I, Sun LZ*. Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression. Clin Cancer Res. 2020 Mar 15;26(6):1486-1496.
2. Chen J, Zhu J, Xu SJ, Zhou J, Ding XF, Liang Y, Chen G*, Lu HS*. Transmembrane 4 L Six Family Member 1 Suppresses Hormone Receptor--Positive, HER2-Negative Breast Cancer Cell Proliferation. Front Pharmacol. 2022;13:770993.
3. Ding XF, Chen J, Ma HL, Liang Y, Wang YF, Zhang HT, Li X*, Chen G*. KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation. Life Sci. 2022 Mar 15;293:120320.
4. Zhao WJ, Zhu LL, Yang WQ, Xu SJ, Chen J, Ding XF*, Liang Y*, Chen G*. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β. Cancer Sci. 2021 Apr;112(4):1624-1632.
5. Yang WQ, Zhao WJ, Zhu LL, Xu SJ, Zhang XL, Liang Y, Ding XF, Kiselyov A, Chen G*. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression. Front Pharmacol. 2021;12:603453.
6. Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, Chen G*, Liang Y, Zhang Q. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 2020 Dec;132:110821.
7. Ma HL, Yu SJ, Chen J, Ding XF, Chen G*, Liang Y*, Pan JL*. CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue. Biomed Pharmacother. 2020 Jan;121:109578.
8. Shen M#, Chen G#, Xie Q, Li X, Xu H, Wang H, Zhao S. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Urol Int. 2020;104(7-8):533-541.
9. Chen G*, Ding XF, Bouamar H, Pressley K, Sun LZ*. Everolimus induces G1 cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells. Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C244-C252.
10. Chen G, Bouamar H, Sun LZ*. Isolation, Culture, and Differentiation of Mammary Epithelial Stem/Progenitor Cells from Fresh or Ex Vivo Cultured Human Breast Tissue. Curr Protoc Cell Biol. 2019 Mar;82(1): e65.
11. Chen G, Zhou J, Chen J, Zhu J, Liu SC, Ding XF, Zhang Q. VHL regulates NEK1 via both HIF-2α pathway and ubiquitin-proteasome pathway in renal cancer cell. Biochem Biophys Res Commun. 2019 Feb 12;509(3):797-802.
12. Ding XF, Chen J, Zhou J, Chen G*, Wu YL*. Never-in-mitosis A-related kinase 8, a novel target of von-Hippel-Lindau tumor suppressor protein, promotes gastric cancer cell proliferation. Oncol Lett. 2018 Nov;16(5):5900-5906.
13. Ding XF, Zhou J, Chen G*, Wu YL*. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells. Mol Med Rep. 2018 Jul;18(1):1206-1210.
14. Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL, Dere R. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017 Jun 15;36(24):3450-3463
15. Chen G, Xu JY, Chen J, Zhang JX, Zhou J, Liang Y, Ding XF*. Loss of PIG3 increases HIF-1α level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells. Oncotarget. 2016 May 10;7(19):27176-84.
16. Zhou J, He LL, Ding XF, Yuan QQ, Zhang JX, Liu SC*, Chen G*. Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells. Biomed Res Int. 2016;2016:6723807.
17. Ding XF, Yin DQ, Chen Q, Zhang HY, Zhou J, Chen G*. Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts. Tumour Biol. 2015 Mar;36(3):1463-9.
18. Ding XF, Zhou J, Hu QY, Liu SC, Chen G*. The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells. J Biol Chem. 2015 Jan 16;290(3):1389-94.
19. Shen M, Jia W, Lin C, Fan G, Jin Y, Chen X, Chen G*. Facile synthesis of folate-conjugated magnetic/fluorescent bifunctional microspheres. Nanoscale Res Lett. 2014;9(1):558.
20. Ding XF, Shen M, Xu LY, Dong JH, Chen G*. 13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-β-elemene, a novel β-elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells. Oncol Lett. 2013 May;5(5):1554-1558.
21. Chen G#, Chen SM#, Wang X, Ding XF, Ding J, Meng LH. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem. 2012 Apr 6;287(15):12132-41.
22. Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, Li YX, Meng LH*, Ding J*. Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med (Berl). 2010 Sep;88(9):941-52.
主持的科研项目：
1. 国家自然科学基金，NEK-1和NEK-8参与介导pVHL维持肾癌细胞原纤毛结构稳定的机制研究（81201530），2013-01至2015-12。
2. 浙江省自然科学基金，靶向mTOR信号通路干预CXCL12/CXCR4功能轴介导的胃癌转移的研究（Y2110474），2012-01至2013-12。
3. 浙江省自然科学基金，pVHL促进AURKA蛋白泛素化降解的机制研究(Y15H310006)，2015-01至2017-12。
4. 浙江省公益性应用研究计划项目，乳腺“癌前”病变动物模型制备及其在乳腺癌早期诊断和早期治疗中的应用研究（2018C37109），2018-01至2020-12。
5. 浙江省自然科学基金，新型DCLK1激酶抑制剂筛选模型构建及候选化合物YJM-43抗肺癌作用机制研究（HDMY22H310084），2022-01 至 2024-12。
6. 浙江省普通本科高校“十四五”首批新医科重点教材建设项目，《医学机能学实验》新形态教材，2023-01 至 2024-12。
7. 教育部产学合作协同育人项目（220506291302513），2022-07至2024-06。
联系方式：
地址：浙江省台州市市府大道1139号医学院A-213室
邮箱：gchen@tzc.edu.cn
